Scholarlink

<p>Management of metabolic diseases, such as obesity and type 2 diabetes, typically requires pharmacotherapeutics in addition to lifestyle changes. Several glucagon-like peptide-1 receptor (GLP-1R) agonists have acquired US FDA approval for treatment of these diseases, based on efficacy in glycaemic control and weight management in randomised controlled trials (RCTs). Recently, poly-agonist drugs that target GLP-1R and other metabolic signalling pathways, such as glucose-dependent insulinotropic receptors and glucagon receptors, have shown superior glycaemic control and weight loss effects compared with mono-agonist drugs in RCTs. This highlights the potential benefit of activating multiple gut hormone signalling pathways to achieve improved outcomes in the pharmacological treatment of metabolic diseases.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treat metabolic diseases with effective and approved therapies while new treatments are under investigation

  • 期刊论文

  • 发表日期：

    2025年4月11日

查看全文
  • Aisling McGuigan

摘要

Management of metabolic diseases, such as obesity and type 2 diabetes, typically requires pharmacotherapeutics in addition to lifestyle changes. Several glucagon-like peptide-1 receptor (GLP-1R) agonists have acquired US FDA approval for treatment of these diseases, based on efficacy in glycaemic control and weight management in randomised controlled trials (RCTs). Recently, poly-agonist drugs that target GLP-1R and other metabolic signalling pathways, such as glucose-dependent insulinotropic receptors and glucagon receptors, have shown superior glycaemic control and weight loss effects compared with mono-agonist drugs in RCTs. This highlights the potential benefit of activating multiple gut hormone signalling pathways to achieve improved outcomes in the pharmacological treatment of metabolic diseases.